FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2914809898> ?p ?o ?g. }

• W2914809898 endingPage "S292" @default.
• W2914809898 startingPage "S291" @default.
• W2914809898 abstract "The majority of bone marrow transplants (BMTs) utilize granulocyte-colony stimulating factor (G-CSF) mobilized peripheral blood (mPB) as the source of hematopoietic stem cells (HSCs). Mobilization with G-CSF requires a multi-day dosing regimen and fails to mobilize a large proportion of CD34+CD90+CD45RA- HSCs, the cell type responsible for hematopoietic engraftment. Moreover, up to 80% of allogenic recipients will experience significant side effects such as acute graft-versus-host disease (GvHD), even though G-CSF mPB contains a small and variable number of immunosuppressive monocytes (Vendramin et al., BBMT 2014). Identification of a mobilizing regimen that consistently and rapidly produces high numbers of HSCs and immunosuppressive monocytes without the need for G-CSF would be ideal. We previously reported that MGTA-145, a CXCR2 agonist, rapidly mobilizes HSCs when combined with the CXCR4 inhibitor, plerixafor (Blood 2017 130:1920). In the present study, detailed profiling was performed at 0 through 24 hours after mobilization of non-human primates (NHPs) with a single dose of MGTA-145, plerixafor, or MGTA-145 plus plerixafor versus a multi-dose, five-day regimen of G-CSF.MGTA-145 plus plerixafor led to a 19-fold increase in number of CD34+CD90+CD45RA- HSCs within four hours of dosing (p<0.001, n=13, Figure 1A), corresponding to 4-fold higher numbers than obtained by G-CSF alone, and resulting in rapid engraftment in an autologous NHP transplant. Immune profiling of graft subsets revealed a 19-fold increase over baseline in the number of CD34dim monocytes within four hours of dosing (p<0.001, n=13, Figure 1A) that suppressed T cell proliferation in vitro (p<0.05). Frequency and number of CD34dim monocytes was 2-3 fold higher with MGTA-145 plus plerixafor versus G-CSF or plerixafor alone (p<0.01, n=3-5) and correlated with HSC mobilization (p<0.001). To test immunosuppressive capabilities in vivo, we transplanted 6 × 106 peripheral blood mononuclear cells (PBMCs) isolated from naïve unmobilized NHPs or NHPs mobilized with G-CSF or MGTA-145 plus plerixafor. NSG mice transplanted with unmobilized PBMCs had significantly higher number of T cells and increased T cell activation in vivo. Notably, all (13/13) mice transplanted with unmobilized PBMCs died of acute GvHD compared to 2/6 mice transplanted with G-CSF PBMCs and 1/8 mice transplanted with MGTA-145 plus plerixafor PBMCs (Figure 1B, p<0.001). PBMCs depleted of CD34dim monocytes were transplanted into NSG mice to assess whether this immunosuppressive effect is due to CD34dim monocytes.As the risk of GvHD remains a significant clinical problem in the allogenic setting, MGTA-145 plus plerixafor may rapidly mobilize an advantageous graft relative to the standard of care, G-CSF, since MGTA-145 plus plerixafor results in significantly higher numbers of both engraftable HSCs and highly immunosuppressive monocytes. The majority of bone marrow transplants (BMTs) utilize granulocyte-colony stimulating factor (G-CSF) mobilized peripheral blood (mPB) as the source of hematopoietic stem cells (HSCs). Mobilization with G-CSF requires a multi-day dosing regimen and fails to mobilize a large proportion of CD34+CD90+CD45RA- HSCs, the cell type responsible for hematopoietic engraftment. Moreover, up to 80% of allogenic recipients will experience significant side effects such as acute graft-versus-host disease (GvHD), even though G-CSF mPB contains a small and variable number of immunosuppressive monocytes (Vendramin et al., BBMT 2014). Identification of a mobilizing regimen that consistently and rapidly produces high numbers of HSCs and immunosuppressive monocytes without the need for G-CSF would be ideal. We previously reported that MGTA-145, a CXCR2 agonist, rapidly mobilizes HSCs when combined with the CXCR4 inhibitor, plerixafor (Blood 2017 130:1920). In the present study, detailed profiling was performed at 0 through 24 hours after mobilization of non-human primates (NHPs) with a single dose of MGTA-145, plerixafor, or MGTA-145 plus plerixafor versus a multi-dose, five-day regimen of G-CSF. MGTA-145 plus plerixafor led to a 19-fold increase in number of CD34+CD90+CD45RA- HSCs within four hours of dosing (p<0.001, n=13, Figure 1A), corresponding to 4-fold higher numbers than obtained by G-CSF alone, and resulting in rapid engraftment in an autologous NHP transplant. Immune profiling of graft subsets revealed a 19-fold increase over baseline in the number of CD34dim monocytes within four hours of dosing (p<0.001, n=13, Figure 1A) that suppressed T cell proliferation in vitro (p<0.05). Frequency and number of CD34dim monocytes was 2-3 fold higher with MGTA-145 plus plerixafor versus G-CSF or plerixafor alone (p<0.01, n=3-5) and correlated with HSC mobilization (p<0.001). To test immunosuppressive capabilities in vivo, we transplanted 6 × 106 peripheral blood mononuclear cells (PBMCs) isolated from naïve unmobilized NHPs or NHPs mobilized with G-CSF or MGTA-145 plus plerixafor. NSG mice transplanted with unmobilized PBMCs had significantly higher number of T cells and increased T cell activation in vivo. Notably, all (13/13) mice transplanted with unmobilized PBMCs died of acute GvHD compared to 2/6 mice transplanted with G-CSF PBMCs and 1/8 mice transplanted with MGTA-145 plus plerixafor PBMCs (Figure 1B, p<0.001). PBMCs depleted of CD34dim monocytes were transplanted into NSG mice to assess whether this immunosuppressive effect is due to CD34dim monocytes. As the risk of GvHD remains a significant clinical problem in the allogenic setting, MGTA-145 plus plerixafor may rapidly mobilize an advantageous graft relative to the standard of care, G-CSF, since MGTA-145 plus plerixafor results in significantly higher numbers of both engraftable HSCs and highly immunosuppressive monocytes. Figure 1." @default.
• W2914809898 created "2019-02-21" @default.
• W2914809898 creator A5002264328 @default.
• W2914809898 creator A5037078524 @default.
• W2914809898 creator A5040518837 @default.
• W2914809898 creator A5058498730 @default.
• W2914809898 creator A5066556669 @default.
• W2914809898 creator A5077686993 @default.
• W2914809898 creator A5090936468 @default.
• W2914809898 date "2019-03-01" @default.
• W2914809898 modified "2023-09-26" @default.
• W2914809898 title "Co-Administration of Mgta-145 and Plerixafor Rapidly Mobilizes High Numbers of Hematopoietic Stem Cells and Graft-Versus-Host Disease Inhibiting Monocytic Cells in Non-Human Primates" @default.
• W2914809898 doi "https://doi.org/10.1016/j.bbmt.2018.12.667" @default.
• W2914809898 hasPublicationYear "2019" @default.
• W2914809898 type Work @default.
• W2914809898 sameAs 2914809898 @default.
• W2914809898 citedByCount "1" @default.
• W2914809898 countsByYear W29148098982019 @default.
• W2914809898 crossrefType "journal-article" @default.
• W2914809898 hasAuthorship W2914809898A5002264328 @default.
• W2914809898 hasAuthorship W2914809898A5037078524 @default.
• W2914809898 hasAuthorship W2914809898A5040518837 @default.
• W2914809898 hasAuthorship W2914809898A5058498730 @default.
• W2914809898 hasAuthorship W2914809898A5066556669 @default.
• W2914809898 hasAuthorship W2914809898A5077686993 @default.
• W2914809898 hasAuthorship W2914809898A5090936468 @default.
• W2914809898 hasBestOaLocation W29148098981 @default.
• W2914809898 hasConcept C10205521 @default.
• W2914809898 hasConcept C109159458 @default.
• W2914809898 hasConcept C126322002 @default.
• W2914809898 hasConcept C129470790 @default.
• W2914809898 hasConcept C13373296 @default.
• W2914809898 hasConcept C203014093 @default.
• W2914809898 hasConcept C2776694085 @default.
• W2914809898 hasConcept C2777408962 @default.
• W2914809898 hasConcept C2777767877 @default.
• W2914809898 hasConcept C2778828106 @default.
• W2914809898 hasConcept C2779972918 @default.
• W2914809898 hasConcept C2781413609 @default.
• W2914809898 hasConcept C28328180 @default.
• W2914809898 hasConcept C2911091166 @default.
• W2914809898 hasConcept C54355233 @default.
• W2914809898 hasConcept C71924100 @default.
• W2914809898 hasConcept C86803240 @default.
• W2914809898 hasConcept C8891405 @default.
• W2914809898 hasConcept C98274493 @default.
• W2914809898 hasConceptScore W2914809898C10205521 @default.
• W2914809898 hasConceptScore W2914809898C109159458 @default.
• W2914809898 hasConceptScore W2914809898C126322002 @default.
• W2914809898 hasConceptScore W2914809898C129470790 @default.
• W2914809898 hasConceptScore W2914809898C13373296 @default.
• W2914809898 hasConceptScore W2914809898C203014093 @default.
• W2914809898 hasConceptScore W2914809898C2776694085 @default.
• W2914809898 hasConceptScore W2914809898C2777408962 @default.
• W2914809898 hasConceptScore W2914809898C2777767877 @default.
• W2914809898 hasConceptScore W2914809898C2778828106 @default.
• W2914809898 hasConceptScore W2914809898C2779972918 @default.
• W2914809898 hasConceptScore W2914809898C2781413609 @default.
• W2914809898 hasConceptScore W2914809898C28328180 @default.
• W2914809898 hasConceptScore W2914809898C2911091166 @default.
• W2914809898 hasConceptScore W2914809898C54355233 @default.
• W2914809898 hasConceptScore W2914809898C71924100 @default.
• W2914809898 hasConceptScore W2914809898C86803240 @default.
• W2914809898 hasConceptScore W2914809898C8891405 @default.
• W2914809898 hasConceptScore W2914809898C98274493 @default.
• W2914809898 hasIssue "3" @default.
• W2914809898 hasLocation W29148098981 @default.
• W2914809898 hasOpenAccess W2914809898 @default.
• W2914809898 hasPrimaryLocation W29148098981 @default.
• W2914809898 hasRelatedWork W1980069749 @default.
• W2914809898 hasRelatedWork W1998234776 @default.
• W2914809898 hasRelatedWork W2000125803 @default.
• W2914809898 hasRelatedWork W2113899987 @default.
• W2914809898 hasRelatedWork W2158093070 @default.
• W2914809898 hasRelatedWork W2495570643 @default.
• W2914809898 hasRelatedWork W2967245375 @default.
• W2914809898 hasRelatedWork W4239901736 @default.
• W2914809898 hasRelatedWork W4244863593 @default.
• W2914809898 hasRelatedWork W979357040 @default.
• W2914809898 hasVolume "25" @default.
• W2914809898 isParatext "false" @default.
• W2914809898 isRetracted "false" @default.
• W2914809898 magId "2914809898" @default.
• W2914809898 workType "article" @default.